BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Summary: Partial clinical hold of BioNTech SE’s BNT326/YL202 for the treatment of patients with solid
Summary: Partial clinical hold of BioNTech SE’s BNT326/YL202 for the treatment of patients with solid
Sean Gallup The U.S. FDA has lifted a partial clinical hold on a phase 1
JHVEPhoto The U.S. Food and Drug Administration (FDA) is expected to greenlight newly adjusted COVID
PM Images/DigitalVision via Getty Images Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced Friday that a Phase
Matteo Colombo Morgan Stanley downgraded Maravai LifeSciences Holdings (NASDAQ:MRVI) to Equal Weight from Overweight on
Sean Gallup/Getty Images News The University of Pennsylvania has sued BioNTech (NASDAQ:BNTX) accusing the German
Summary: BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from
U. J. Alexander Shares of Genmab (GMAB) fell 7% Monday after the Danish biotech announced
BioNTech press release (NASDAQ:BNTX): Q2 GAAP EPS of -€3.36. Revenue of €128.7M (-23.3% Y/Y). Reiterates
BioNTech (NASDAQ:BNTX) is scheduled to announce Q2 earnings results on Monday, August 5th, before market